Anatara Lifesciences (ASX:ANR) has updated investors on an analysis following the completion of Stage 2 of its GaRP-IBS (Irritable Bowel Syndrome) trial. …
Anatara provides update following completion of analysis of Phase 2 GaRP-IBS clinical trial
April 22, 2025 Australian Biotech
Latest Video
New Stories
-
The symptoms have been identified, but the widely held belief about the cause is a miss
September 30, 2025 - - Latest News -
UK companies are granted more time to decide on pricing agreement
September 29, 2025 - - Latest News -
Anatara strengthens board with the appointment of Dirk van Dissel
September 29, 2025 - - Australian Biotech -
CLINUVEL advances next-generation peptide drug formulations
September 29, 2025 - -
Alterity Therapeutics targets major market with ATH434 in Multiple System Atrophy
September 29, 2025 - - Australian Biotech -
Lower than expected uptake of new therapies impacts PBS spend
September 29, 2025 - - Latest News -
Chimeric reports encouraging early data from CHM CDH17 trial
September 29, 2025 - - Australian Biotech